A B C D E F Supplementary Fig. 2. Gating strategy for CD44+CD24+ ID8agg tumor initiating cells (TIC). Cells were gated on CD44. CD44 positive cells were.

Slides:

Advertisements

Similar presentations

Fig. 16-CO, p Fig. 16-1, p. 450 Fig. 16-2, p. 450.

Advertisements

Isotype control Supplementary Figure S1. Strategy for gating CD11b+CD14-CD33+CD40+ myeloid cells. Singlets were gated from live cells shown in forward.

P Fig. 6-1, p. 193 Fig. 6-2, p. 193 Fig. 6-3, p. 195.

Figure 1.1 The observer in the truck sees the ball move in a vertical path when thrown upward. (b) The Earth observer views the path of the ball as a parabola.

IFNγIL-2TNFaIL-17A CD40 L MOPP DMSO CD4+ Supplemental figure 5A SEB isotype control isotype control isotype control CD69+ A.

Isotype ControlCD126 NA A B Supplementary Figure 1. CD126 expression on CLL cells. (A) A representative FACS plot of the isotype control and CD126 staining.

CFSE B16-ova Annexin V 7AAD +Th17 TGF-  1 +Th17 IL-1  +Th17 TGF-  1 +Th17 IL-1  No T cells a EL-4 B16-ova EL-4 CFSE gated Supplementary figure 1 CD25.

SSC -A SLAN CD16 CD14 CD3-CD19-CD56 CD123 HLA-DR CD33

BET-EFF (MV-4-11): Sacrificing 2 Sick Mice – Tumor Burden

BET-EFF (MV-4-11): Sacrificing 4 Sick Mice – Tumor Burden

Supplementary Figure 2 Anti-PD-L1 (avelumab) enhances CD8 activation and decreases CD4 to a greater extent than commercially available anti-PD-L1 blocking.

% of Suppression a-TGFb (ug/ml) Tr/Tresp 1:1 1:4

A. BCL6 Intensity Score Bin B. CD7 Intensity Score Bin C.

Anti-CD40 and CpG induce activation of T cells in draining lymph nodes

Collaboration is required for successful immunotherapy

Supplementary figure 1. Gating strategy used for FACS sorting of TIL subsets (CD3+, CD3+CD8+/-, CD3+CD8+PD-1+/-). Two representative fresh tumor samples.

A B C D CD4+ CD8+ Control Isotype Ab Anti-TNFa Ab Control Isotype Ab

Reduced endothelial progenitor cells in extracranial arterial stenosis but not intracranial arterial stenosis Zhixin Huang, MD, PhD, Xiaohao Zhang, MD,

A B A B C Supplementary Fig. 8 Supplementary Fig. 9

Expression of PD-L1 in mastocytosis

Ret mouse very large tumors (VLTs) display altered ratios of infiltrating memory to naive T cells: Roles in tumor expansion Mohammad W. Khan, Viktor.

A B C D E F Supplementary Fig. 1. Gating strategy for CD44+CD133+CD24+ B16 tumor initiating cells (TIC). Cells were gated on CD44. CD44 positive cells.

Figure S2 Gating strategy of AT2 cells based on EpCAM and MHCII

Natural regulatory T cells in isolated early responders compared with dual responders with allergic asthma Takashi Kinoshita, MD, Adrian Baatjes, MSc,

Combined A2A receptor and PD-1 blockade is not effective in IFNγ−/− mice. Combined A2A receptor and PD-1 blockade is not effective in IFNγ−/− mice. AT-3ovadim.

Fig. 8. mRIPO elicits neutrophil influx followed by DC and T cell infiltration into tumors. mRIPO elicits neutrophil influx followed by DC and T cell infiltration.

MR1 inhibits anti-MTg autoantibody responses in CD28−/− NOD

Figure 2S (Supplementary Data)

Human Treg cells express PlexinB1.

Increased chemokine content and leukocyte infiltrate in D6-negative tumors. Increased chemokine content and leukocyte infiltrate in D6-negative tumors.

Supplementary figure1. CK7 CK20 CDX2 DPEP1 Cut off value: 85%

Tregs and APC subsets in TDLNs of patients with cervical cancer.

STAT3 regulates IgE class switching in a Th2-type response.

Supplemental Digital Content 2 – Figure 1

Tetramer staining performed to determine frequencies of epitope-specific T cells after clearance of HPV16 infection but prior to isolation of T-cell clones.

Supplemental Digital Content 3 – Figure 2

Anti-tumor effect of anti-PD-1 antibody against SCC3 tumor

TNFα-producing CD3+CD4+CD44+ infiltrating cells.

CD4+ CD56+ Blastic Tumor Cells Express CD101 Molecules

Ret mouse very large tumors (VLTs) display altered ratios of infiltrating memory to naive T cells: Roles in tumor expansion Mohammad W. Khan, Viktor.

Supplementary Table 1. Summary of surface marker expression of adherent (A) and sphere-forming MRT cell lines (B), and primary tumors (C). A Sample CD146.

PD-1–PD-L1 axis is highly expressed and is not IFNγ-dependent in a subcutaneous murine model of PDA. A, experimental design for establishment of subcutaneous.

CD8+ T cells were immunomodulated and required for the efficacy of anti–4-1BB/anti–PD-1 combination treatment. CD8+ T cells were immunomodulated and required.

Introduction. Activation of HIV-Specific CD8+ T Cells from HIV+ Donors by Vesatolimod.

Changes in regulatory B-cell levels in bone marrow, blood, and sputum of patients with asthma following inhaled allergen challenge John-Paul Oliveria,

C A B * * * * HCC1954 HCC1569 Supplementary-Figure S5 Tumor cells sc.

Socs1 KD tumors exhibit a more T-cell–inflamed phenotype and increased T-cell activation. Socs1 KD tumors exhibit a more T-cell–inflamed phenotype and.

Flow cytometry of subcutaneous adipose tissue stromovascular cells.

A B C D E F Supplementary Fig. 3. Gating strategy for ES2 ALDHhi tumor initiating cells (TIC). Cells were treated with the specific aldehyde dehydrogenase.

PD1 targeting alters the recruitment of immune cells to MC38 CRC tumors. PD1 targeting alters the recruitment of immune cells to MC38 CRC tumors. MC38.

MR1Ts recognized by the hpMR1+EC tetramer are more likely to be TRAV1-2−. MR1Ts recognized by the hpMR1+EC tetramer are more likely to be TRAV1-2−. PBMCs.

Conversion of CD11bhighCD27high NK cells into MDSCs leads to CD11bhighCD27high and CD11bhighCD27low NK cell reduction. Conversion of CD11bhighCD27high.

Geographic colocalization of PD-L1+ tumor cells with infiltrating immune cells in MCC. The predominant pattern of tumor cell PD-L1 expression is at the.

Fig. 3. On pathology examination, (a) low-power field (× 40) and (b) high-power field (× 200) images of the tumor reveal biphasic proliferation and a multinodular.

Fig. 3. A photomicrograph shows the combination of the numerous, inter-anastomosing vascular spaces and more solid, spindle-cell areas effacing the normal.

CD11bhighCD27high conventional NK cells are converted into MDSCs

PVHA increased anti-PD-L1–mediated growth inhibition in 4T1/HAS3 tumors. PVHA increased anti-PD-L1–mediated growth inhibition in 4T1/HAS3 tumors. A, 4T1/HAS3.

CD4+ and CD8+ TILs express surface CD137.

Immunophenotypic analysis of TILs in B16 and K1735 melanoma following combination therapy with antibodies targeting PS and PD-1. Immunophenotypic analysis.

PD-1 and CD103 are coexpressed on CD8+ T cells but demonstrate distinct mechanisms of regulation. PD-1 and CD103 are coexpressed on CD8+ T cells but demonstrate.

Immune profiling of patient-derived organotypic tumor spheroids.

Intratumoral injections of small doses of agonist anti-CD137 mAb to directly act on CD137+ TILs render systemic immunotherapeutic effects that are synergistic.

Moderate-affinity vaccine antigens elicited greatest antitumor response. Moderate-affinity vaccine antigens elicited greatest antitumor response. Wild-type.

Supplementary Table 2. Antibodies and conditions used for the IHC studies.

IL2Cx alone or in combination with anti–CTLA-4 increases the CD8/Treg ratio in the tumor. IL2Cx alone or in combination with anti–CTLA-4 increases the.

Supplementary Table 1. TTI-621 binds to human tumor cell lines

H & E = hematoxylin and eosin.

Technology schematic for phenotypic tracking of single molecularly defined B-lineage clones. Technology schematic for phenotypic tracking of single molecularly.

Bezafibrate increases the number of effector CTLs by enhancing their survival capacity and proliferation. Bezafibrate increases the number of effector.

Supplementary Figures

Presentation transcript:

A B C D E F Supplementary Fig. 2. Gating strategy for CD44+CD24+ ID8agg tumor initiating cells (TIC). Cells were gated on CD44. CD44 positive cells were then gated on CD24, considered as TIC. (A) Isotype controls for CD44, CD24, ID8agg control. (B) CD44, CD24 staining on ID8agg control cells. (C) Isotype controls for CD44, CD24, ID8agg PD-L1lo clone 3. (D) CD44, CD24 staining on ID8agg PD-L1lo clone 3 cells. (E) Isotype controls for CD44, CD24, ID8agg PD-L1lo clone 6. (F) CD44, CD24 staining on ID8agg PD-L1lo clone 6 cells.